What Current Research Actually Shows
Fibromyalgia is one of the most misunderstood chronic illnesses in modern medicine. It affects millions of people worldwide and is characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive difficulties often referred to as “fibro fog.” Despite its prevalence, the underlying cause of fibromyalgia remains an ongoing subject of research and debate.
For decades, fibromyalgia has been classified as a nociplastic pain condition, meaning the pain originates from altered processing in the nervous system rather than tissue damage or inflammation. However, emerging research over the past several years has raised an important question: Could immune system dysfunction play a role in fibromyalgia?
Recent studies in rheumatology, neurology, and chronic pain research suggest that immune abnormalities, including autoantibodies and inflammatory signaling, may contribute to fibromyalgia symptoms in at least some patients. At the same time, evidence remains mixed, and fibromyalgia is not currently classified as an autoimmune disease.
Understanding where the science stands today requires examining both the evidence supporting an immune connection and the limitations of current research.
The Traditional Understanding of Fibromyalgia
Historically, fibromyalgia has been viewed primarily as a disorder of central sensitization. Central sensitization refers to a condition in which the brain and spinal cord amplify pain signals, causing the body to perceive normal sensations as painful. This altered pain processing can lead to the widespread pain and tenderness commonly experienced by fibromyalgia patients.
The International Association for the Study of Pain classifies fibromyalgia under nociplastic pain, which occurs when the nervous system processes pain abnormally despite the absence of tissue damage or nerve injury (Paroli, Gioia, Accapezzato, & Caccavale, 2024).
Research supporting this model includes neuroimaging studies showing increased activity in brain regions responsible for pain processing, as well as abnormalities in neurotransmitters such as serotonin and norepinephrine. These findings have helped shape current treatment approaches, which often focus on medications that affect nervous system signaling and therapies aimed at reducing central pain amplification.
However, the central sensitization model does not fully explain all aspects of fibromyalgia. Many patients report symptoms that extend beyond pain processing, including immune-related symptoms, persistent fatigue, and overlap with other inflammatory conditions. These observations have prompted researchers to investigate whether additional biological mechanisms may be involved.
New Evidence Linking Fibromyalgia and the Immune System
In recent years, several studies have begun exploring whether immune system activity could contribute to fibromyalgia symptoms. While this research is still developing, some findings have been particularly significant.
Autoantibodies and Pain Signaling
One of the most notable discoveries involves the role of immunoglobulin G (IgG) antibodies. Antibodies are proteins produced by the immune system to identify and neutralize pathogens such as bacteria and viruses. In autoimmune diseases, antibodies mistakenly target the body’s own tissues.
A 2023 study published in the journal Pain investigated whether antibodies from fibromyalgia patients could influence pain signaling. Researchers isolated IgG antibodies from individuals diagnosed with fibromyalgia and transferred them into mice. The results were striking: mice that received fibromyalgia antibodies developed increased pain sensitivity and nerve hypersensitivity (Krock, Morado-Urbina, Menezes, Hunt, Sandström, Kadetoff, Tour, Verma, & Kultima, 2023).
Further analysis revealed that these antibodies bound to satellite glial cells, which are supportive cells surrounding sensory neurons in the dorsal root ganglia. These cells play an important role in regulating pain signals transmitted from the body to the brain.
In addition, the study found that patients with higher levels of these antibodies experienced more severe fibromyalgia symptoms, including greater pain intensity and pressure sensitivity (Krock et al., 2023). This finding suggests that immune activity may influence symptom severity in some individuals.
While this does not prove that fibromyalgia is an autoimmune disease, it provides compelling evidence that immune system factors may contribute to pain mechanisms.
Altered Autoantibody Patterns in Fibromyalgia
Other studies have also examined the presence of autoantibodies in fibromyalgia patients. A pilot study investigating autoantibody signatures found differences in immune markers between individuals with fibromyalgia and healthy control participants (Ryabkova, Churilov, & Shoenfeld, 2023).
Researchers observed alterations in antibodies associated with neural signaling pathways, including those affecting gamma-aminobutyric acid (GABA) receptors. Because GABA plays a key role in regulating nervous system activity, abnormalities in these antibodies could potentially influence pain perception and neurological symptoms.
The study also noted that some fibromyalgia patients showed antibodies targeting spinal ganglia, structures involved in transmitting pain signals from the peripheral nervous system to the brain. However, these antibodies were present only in a subset of patients, highlighting the complexity and heterogeneity of the condition.
Immune Cells and Chronic Pain
Beyond antibodies, several immune cell types have been implicated in fibromyalgia.
Recent research has explored the role of mast cells, neutrophils, and microglia in the development of chronic pain.
Mast cells are immune cells involved in inflammatory responses and allergic reactions. Studies have found increased mast cell numbers in skin biopsies from fibromyalgia patients, suggesting they may contribute to inflammatory signaling in pain pathways (Paroli et al., 2024).
Neutrophils, another type of immune cell, have also been investigated. Experimental studies have shown that transferring neutrophils from fibromyalgia patients into animal models can induce widespread pain sensitivity.
This suggests that immune cells themselves may influence pain amplification mechanisms.
Within the central nervous system, microglia activation has been observed in several chronic pain conditions, including fibromyalgia. Microglia are immune cells that reside in the brain and spinal cord and release inflammatory cytokines when activated. Increased microglial activity has been associated with chronic widespread pain and may contribute to neuroinflammation.
These findings suggest that fibromyalgia may involve a complex interaction between the nervous system and immune system rather than being solely a neurological condition.
Fibromyalgia and Autoimmune Diseases
Another area of research focuses on the relationship between fibromyalgia and established autoimmune disorders.
Fibromyalgia frequently occurs alongside immune-mediated rheumatic diseases, including rheumatoid arthritis, Sjögren’s syndrome, psoriatic arthritis, and spondyloarthritis. Research suggests that fibromyalgia symptoms occur in a significant percentage of patients with these conditions (Mettler, Ming-Azevedo, & Hügle, 2025).
Meta-analyses indicate that fibromyalgia occurs in approximately:
21% of patients with rheumatoid arthritis
13% of patients with axial spondyloarthritis
18% of patients with psoriatic arthritis
(Paroli et al., 2024).
These rates are significantly higher than fibromyalgia prevalence in the general population. This overlap raises the possibility that shared biological pathways may contribute to both conditions.
However, fibromyalgia symptoms in autoimmune diseases are often related to central pain sensitization rather than active autoimmune inflammation. As a result, the presence of fibromyalgia in autoimmune patients does not necessarily mean fibromyalgia itself is autoimmune.
Why Fibromyalgia Is Not Classified as an Autoimmune Disease
Despite emerging evidence linking immune activity to fibromyalgia, the condition is not currently classified as an autoimmune disease. Several reasons explain this.
First, autoimmune diseases typically involve consistent immune attacks on specific tissues or organs. For example, rheumatoid arthritis targets joint tissue, and multiple sclerosis affects the central nervous system. In fibromyalgia, researchers have not identified a consistent tissue target for immune attack.
Second, many fibromyalgia patients do not show abnormal autoimmune markers such as antinuclear antibodies. Studies examining these markers often find levels comparable to those seen in the general population (Ryabkova et al., 2023).
Third, the strongest evidence supporting fibromyalgia still centers on central nervous system pain processing abnormalities. Neuroimaging studies repeatedly demonstrate altered pain processing in the brain, which remains the primary explanation for fibromyalgia symptoms.
Finally, immune-related findings appear to apply only to a subset of patients, rather than representing a universal feature of the disease.
What the Current Research Suggests
Taken together, current evidence suggests that fibromyalgia likely involves multiple biological mechanisms.
Central nervous system sensitization remains the primary driver of widespread pain. However, immune system abnormalities may contribute to symptom development in some individuals.
Autoantibodies targeting satellite glial cells, altered immune signaling, and increased inflammatory activity all suggest that immune processes may influence pain pathways.
Rather than replacing the nociplastic pain model, these findings suggest that fibromyalgia may involve a combination of neurological and immune factors.
Future research will likely focus on identifying biomarkers that can distinguish different fibromyalgia subtypes. This could eventually lead to more personalized treatment approaches that target specific biological pathways.
Conclusion
Fibromyalgia remains a complex and multifaceted chronic illness. While it is still classified as a nociplastic pain disorder, recent research suggests that immune system activity may play a role in symptom development for some patients.
Studies involving antibody transfer experiments, altered immune markers, and increased inflammatory signaling all point toward possible immune involvement. At the same time, the current evidence does not support classifying fibromyalgia as a primary autoimmune disease.
Instead, fibromyalgia likely reflects an interaction between nervous system dysfunction and immune system activity, highlighting the need for continued research.
Understanding these mechanisms is critical not only for improving treatment strategies but also for shifting the broader conversation about fibromyalgia toward a more accurate, biology-based understanding of the condition.
References
Krock, E., Morado-Urbina, C. E., Menezes, J., Hunt, M. A., Sandström, A., Kadetoff, D., Tour, J., Verma, V., & Kultima, K. (2023). Fibromyalgia patients with elevated levels of anti-satellite glia cell immunoglobulin G antibodies present with more severe symptoms. Pain, 164(8), 1828–1840. https://doi.org/10.1097/j.pain.0000000000002881.
Mettler, J., Ming-Azevedo, P., & Hügle, T. (2025). Fibromyalgia with concomitant immune-mediated rheumatic diseases: An evaluation of clinical characteristics, diagnostic criteria and multimodal treatment outcomes. Advances in Rheumatology, 65(27). https://doi.org/10.1186/s42358-025-00457-4.
Paroli, M., Gioia, C., Accapezzato, D., & Caccavale, R. (2024). Inflammation, autoimmunity, and infection in fibromyalgia: A narrative review. International Journal of Molecular Sciences, 25(11), 5922. https://doi.org/10.3390/ijms25115922.
Ryabkova, V. A., Churilov, L. P., & Shoenfeld, Y. (2023). Autoantibody correlation signatures in fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome: Association with symptom severity. Autoimmunity Reviews, 22, 103364.
Leave a Reply